|
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Ruth Gabriela Herrera-Gómez |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Innate Pharma; Merck Serono |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MERCK SERONO (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; Novartis |
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Innate Pharma; MSD Oncology |